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Abstract: Idiopathic pulmonary fibrosis (IPF) is age-related interstitial lung disease of unknown
etiology. About 100,000 people in the U.S have IPF, with a 3-year median life expectancy post-diagnosis.
The development of an effective treatment for pulmonary fibrosis will require an improved
understanding of its molecular pathogenesis and the “normal” and “pathological’ hallmarks of
the aging lung. An important characteristic of the aging organism is its lowered capacity to adapt
quickly to, and counteract, disturbances. While it is likely that DNA damage, chronic endoplasmic
reticulum (ER) stress, and accumulation of heat shock proteins are capable of initiating tissue
repair, recent studies point to a pathogenic role for mitochondrial dysfunction in the development
of pulmonary fibrosis. These studies suggest that damage to the mitochondria induces fibrotic
remodeling through a variety of mechanisms including the activation of apoptotic and inflammatory
pathways. Mitochondrial quality control (MQC) has been demonstrated to play an important role
in the maintenance of mitochondrial homeostasis. Different factors can induce MQC, including
mitochondrial DNA damage, proteostasis dysfunction, and mitochondrial protein translational
inhibition. MQC constitutes a complex signaling response that affects mitochondrial biogenesis,
mitophagy, fusion/fission and the mitochondrial unfolded protein response (UPRmt) that, together,
can produce new mitochondria, degrade the components of the oxidative complex or clearance the
entire organelle. In pulmonary fibrosis, defects in mitophagy and mitochondrial biogenesis have been
implicated in both cellular apoptosis and senescence during tissue repair. MQC has also been found
to have a role in the regulation of other protein activity, inflammatory mediators, latent growth factors,
and anti-fibrotic growth factors. In this review, we delineated the role of MQC in the pathogenesis of
age-related pulmonary fibrosis.
Keywords: mitochondria; quality control; mitophagy; proteostasis; biogenesis
1. Introduction
Idiopathic pulmonary fibrosis (IPF) represents one of the most aggressive and irreversible lung
diseases, usually diagnosed in the fifth decade of life, carries a very poor prognosis, an unknown etiology
and limited therapeutic options [1]. Metabolic alterations seen in aging have also been found in the
lungs of patients with IPF, raising the possibility that aging may contribute to the IPF pathogenesis [2].
Alveolar epithelial cells (AEC) of IPF lungs have shown to exhibit short telomeres, predisposing these
cells to apoptosis, leading to abnormal parenchymal architecture, dysfunctional re-epithelialization
and exaggerated inflammatory reaction that contributes to the development of fibrotic scarring.
In addition, fibroblast of IPF lungs showed abnormal cellular morphology with reduced mitochondrial
mass, disrupted membranes and severe ruptured cristae, prompting the fibroblasts to maladaptive
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responses to stress after injury and increasing susceptibility to fibrosis. Among these alterations,
mitochondria dysfunction is recognized as a major hallmark that accounts for the predilection to
fibrosis in aging [3]. While mitochondria were initially viewed as just the powerhouse of the cell,
advances in the field has allowed us to understand the multiple roles of this organelle. Mitochondria
are involved in the heme biosynthesis, intracellular calcium regulation, ATP-production and fatty
acid synthesis. Thus, to guarantee adequate organelle function and maintenance of intracellular
homeostasis, mitochondria rely on quality control pathways: mitochondrial biogenesis, fusion/fission,
mitophagy and the mitochondrial unfolded protein response (UPRmt). Biogenesis of mitochondria
allows proper cellular homeostasis, it relies on the action of PGC-1a, the major regulator of this
process and its activation via different proteins (AMPK, SIRT1, MAPK and CREB). Fusion/Fission
represents the cornerstone of mitochondria dynamics by controlling the cellular bioenergetics and
mitochondrial networks via the actions of Drp1, Fis1, Mff, Mfn1 and Mfn2. Selective removal of
damaged and dysfunctional mitochondria requires the coordinated action between PINK1/Parkin
pathway activation. Accumulation of unfolded proteins inside the mitochondria leads to activation of
the mitochondria unfolded protein response (UPRmt) with the goal of promoting repair, recovery and
restore mitochondrial proteostasis. Activation of these machineries allows maintenance and regulation
of this organelle metabolism, biogenesis, ROS production and mitochondrial DNA (mtDNA) damage
repair [4,5]. Disruptions of these processes can subsequently lead to the accumulation of dysfunctional
mitochondria, alter the intracellular environment and contribute to the development of age-related
lung fibrosis [6]. While the exact triggering injury leading to irreversible fibrosis seen in IPF is unknown,
dysregulation of the mitochondrial quality systems suggests a clear pathogenic role that could explain
the metabolic dysregulation, proteostatics alterations and decline in mitochondrial function of patients
with IPF. This review explores the mitochondrial quality control pathways, its association with the
development of age-related lung fibrosis and describes new potential therapeutic targets.
2. Mitochondrial Quality Control Pathways
2.1. Mitochondrial Biogenesis
Mitochondria biogenesis is a complex and tightly regulated process. Mitochondrial biogenesis
is defined as increased growth in the number of mitochondria from the growth and division of
pre-existing mitochondria [7]. The major regulator of this process, co-transcriptional factor PGC-1a,
has the ability to activate different transcription factors such as nuclear respiratory factor 1 (NRF-1) and
nuclear respiratory factor 2 (NRF-2) [8]. These transcription factors, in turn, increase the expression of
mitochondrial transcription factor (Tfam), which drives transcription and replication of mitochondrial
DNA (mtDNA) (Figure 1). In response to injury or proteostatic stress, mitochondria biogenesis is
stimulated to increase cellular energy production through AMP-activated protein kinase (AMPK),
a protein considered another major regulator of mitochondrial biogenesis when energy levels inside
the cell decrease [9]. Furthermore, the reduction of AMPK and PGC-1a are a major contributing factor
for the mitochondrial dysfunction evidenced in the bleomycin-induced lung fibrosis model [10,11].
Another mechanism implicated, is through upregulation of the ROS-producing enzyme NADPH
oxidase-4 (Nox4) which represses NRF-2 and Tfam leading to diminished biogenesis [12]. In addition,
experimental models have suggested a direct association between DNA damage causing activation
of injury sensors poly(ADP-ribose) polymerase 1 (PARP-1) and p53 which diminish mitochondrial
biogenesis by inhibiting the expression of PGC-1a [13,14].
Mitochondria biogenesis is closely associated with the mTOR signaling, activation of this pathway
directly leads to increased expression of PGC-1a. Studies have demonstrated that activation of the
mTORC complex 1 (mTORC1) upregulates biogenesis by preventing the binding of the eukaryotic
translation initiation factor 4E (eIF4)-binding proteins (4E-BP) to their targets. As a result, translation
of nuclear-encoded mitochondrial proteins of complex V, complex I and Tfam takes place [15].
Furthermore, mTOR signaling is a highly regulated pathway, proper function and quality control relies
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on the function of the proteasome and ubiquitin-ligases activity to accomplish protein synthesis required
for mitochondria biogenesis. The actions of mTORC1 are carried out within minutes of activation,
coordinating the inhibition of autophagy, promoting protein synthesis, suppressing protein turnover
and activating the transcription factor SREBP1 [16,17]. The underlying mechanisms of how proteolysis
is initially inhibited are unknown It is possible that phosphorylation of E3-ligases by mTORC1 inhibits
ubiquitination and subsequently proteolysis by the 20S subunit of the proteasome. During early
response, inhibition of protein degradation allows the proper stability of newly generated ribosomes and
translation initiation. In the following hours, SREBP1 leads to transcriptional activation of the nuclear
factor erythroid-derived 2-related factor (Nrf1, also known as NFE2L1) which promotes proteasome
gene expression as a delayed response [18]. Therefore, increased protein degradation is seen in the late
stages of the mTORC1 response. Conceivably, the delayed production of proteasomes creates an efficient
clearance of proteins to protect the cell from the accumulation of misfolded-cytotoxic proteins and
simultaneously maintains an adequate pool of recycled amino acids to continue mitochondria biogenesis.
Interaction between mitochondria dysfunction, mTORC1 and the ubiquitin-proteasome system might
represent the key element to understand in depth the mechanism that lead to mitochondrial biogenesis
dysregulation in age-related lung fibrosis.
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Figure 1. Regulation of mitochondria biogenesis. Activation of different signaling pathways, such as
A PK, SIRT1, CREB, MAPK has been associated with mitochondria biogenesis by increasing PGC-1a
gene transcription. PGC-1a represents the major co-transcriptional factor that regulates mitochondria
biogenesis by activating the nuclear respiratory factor 1 (NRF1) and nuclear respiratory factor 2 (NRF2)
which leads to increase expression of mitochondrial transcription factor (Tfam), driving transcription
and replication of mitochondria DNA (mtDNA).
Currently, the role of mitochondria biogenesis in age-related lung fibrosis is not fully elucida ed.
Studies have reporte that with aging, mitochondria biogenesis declines ue to a reduction in PGC-1a,
PGC-1b, AMPK and -53 through senescenc -associated mechanism. (16) Low expr ss on of PGC-1a
was evidenced in patients wi h IPF and fibrotic mouse lungs aft r bleomycin treatment [19]. In addition
Yu et l. demo strated that a rosolized thy oid h rmone (TH) b unted bleomycin and TGF-B-induced
fibrosis in mice. Furthermore, TH was able to restore mitochondrial function and morphology in AECII
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through PINK1 and PGC-1a actions. [20] However, as we demonstrated in our study, mitochondria
biogenesis is increased in the AECII of old mice through the upregulation of the mTORC1/PGC-1
signaling axis. In addition, we found the upregulation of other downstream molecules associated with
mitochondria biogenesis, including Tfam and NRF1. Previous reports have demonstrated that an
increase in mitochondria biogenesis could lead to cellular senescence by enhancing ROS-mediated
damage, as a result of boosting mitochondrial respiration. This is based on the fact that administration
of MitoTempo, following bleomycin exposure in AECII, inhibits the mTORC1 response and suppresses
the expression of senescence markers. Moreover, chronic activation of the mTORC1/PGC-1 axis could
explain the accumulation of large, dysmorphic mitochondria found in the aged mice by over-activating
biogenesis and inhibiting mitophagy to remove defective mitochondria [21]. Although many pieces
remain unsolved, certainly mTORC1/PGC-1 axis represents a potential therapeutic target in the
treatment of age-related lung fibrosis. Further translational studies are needed, nonetheless, current
evidence points that quality control of mitochondria biogenesis plays a crucial role in the pathogenesis
of age-related lung fibrosis, distortions in its regulation can shift the cell towards senescence and
promote inflammation and fibrosis.
2.2. Mitochondrial Dynamics
Mitochondria are dynamic organelles in that they require the balance of fission and fusion for
proper function and adaptation to cell growth, division, and injury response. Fission and fusion
represent the first line of quality control in the setting of proteostatic stress [22,23]. Quality control
of fission and fusion is tied to appropriate cellular bioenergetics and homeostasis of mitochondrial
networks. Fission is carried by the action of dynamin-related protein 1 (Drp1), fission 1 (Fis1),
and mitochondria fission factor (Mff). Fission occurs when Drp1, located in the cytosol or at the
endoplasmic reticulum, is recruited to the OMM where it constricts the mitochondria resulting in two
separate organelles. In order to achieve this, Drp1 requires the formation of a complex through an
interaction with the OMM receptors Fis1 and Mff. Hydrolysis of the Drp1-bound GTP constricts the
Drp1 and allows severing of the enclosed membranes resulting in fission. Moreover, mitochondria
fusion is carried out by proteins mitofusin1 (Mfn1), mitofusin 2 (Mfn2), and optic atrophy 1 (OPA1).
To start this process, proteins Mfn1 and Mfn2, which contain two transmembrane domains in the OMM
with a GTPase domain and are oriented towards the cytoplasm, while OPA1 is found in the IMM and
has a dynamin-related GTPase capacity. Then, mitochondria lipid bilayer mixing is performed in a
Mfn1/Mfn2-dependent manner with a GTP hydrolysis to allow energy for the OMM fusion. Similarly,
IMM fusion requires a similar action by OPA1 to allow merging [24–26].
Age-related lung fibrosis comprises a very complex physiopathology that involves a constant cycle
of injury and repair along with persistent release of pro-inflammatory and pro-fibrotic peptides, which
ultimately lead to mitochondrial dysfunction (Figure 2). Mouse models of IPF have shown increased
mitochondria fusion. This increase in mitochondria fusion leads to alterations of mitochondrial
dynamics by impairing mitophagy and result in the accumulation of dysmorphic mitochondria.
To support this, Bueno et al. reported that AECII in old lungs exhibit enhanced expression of OPA1
and Mfn1 with inactivation of Drp1 in addition to impaired mitophagy and a decline in mitochondrial
function [19]. Also, one suggested mechanism of Drp1 regulation is carried by the E3 ligase MARCH5
and SUMO-1, where ubiquitination and sumolyation stabilizes or recruits Drp1 to modulate fission [27].
Further, the complex formed by Mdm30 with the ubiquitin ligase Skp1-Cullin-F-box (SCF-Mdm30)
regulates the degradation of Mfn1/Mfn2. Similarly, Cilenti et al. determined that the MULAN/MAPL
ligase can modulate mitochondrial morphology by promoting Mfn2 degradation [28,29]. Interestingly,
Radke et al. demonstrated that proteasome inhibition was capable of augmenting mitochondrial
fission [30]. This observation points out a link between the UPS and mitochondrial dynamics. In the
aged lung, it is possible that the activity of the proteasome machinery modulates mitochondrial
morphology and function by restructuring proteostasis along with regulating fusion/fission. Ultimately,
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recognition and deeper understanding of the mechanisms involved could lead to new therapeutic
approaches targeting mitochondria quality control.
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and ultimately leading to mitochondrial dysfunction.
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it is a selective autophagy where damaged and ysfunctional mit chondria are degraded.
This maintains a homeostatic environment between synthesis and degradation of cellular rganelles
and proteins, where byproducts are sent to be recycled in other metabolic pathways [31]. Mitophagy is
crucial in the quality control of mitochondria not only at the rga elle level but also at a cellul r ne,
giv n its association with senescence, apoptosis, a d necroptosis. Impairments in mitophagy have
been associated with multiple diseases, including age-r lated pulmonary fibrosis [6,32].
In the healthy mitochondria, mitophagy relies in the action of PTEN-induced putative kinase 1
(PINK1), a s rine/threonine kin se which is continuously imported to the inner membrane (IM) to
be cleaved and degraded by the mitochondria-specific proteases presenilin-associated rhomboid-lik
protein (PARL) and mitochondrial processing peptidases (MPP) [33–35]. In the setting of mitochondrial
damage, INK1 acts as the initial sensor to activate mitophagy, where stress-induced membrane
dep larization inactivates PARL and MPP. This leads to the stabilization and accumulation of PINK1 on
th outer-mitoch ndrial membr ne (OMM), which allows the kinase domain of PINK1 to phosphorylate
OMM protei s, in addition to recruitment and activation of the E3-ubiquitin ligase Parkin. Once Parkin
is activated, it can p lyubiquitinate proteins to the OMM, including voltage-dependent-anion channel
1 (VDAC1), mitofusin 1 (Mfn1), mitofusin 2 (Mfn2) and mitochondria1 rho 1 (MIRO) in order to be
sub-sequentially phosphorylated by PINK1. The ubiquitination of these proteins on the OM leads to
the formation of the autophagosome by promoting a bridge with microtubule-associated protein 1
light chain 3 (MAP1LC3/LC3) on phagophores through adaptor protei SQSTM1/p62. Additionall ,
the ubiquitination of Mfn1 and Mfn2 result in fission, fragmentation, and subsequent degradati
with mitophagy through the formatio of the autophagosome [36–38].
Mitophagy can also occur independently of Parkin [39–43]. Other receptors such as Bcl2/adenovirus
protein-interacting pr tein 3 (BNIP3), NIX, Cardiolipin, and Fun14 domain containing 1 (FUNDC1) contain
Int. J. Mol. Sci. 2020, 21, 643 6 of 17
an LC3 interacting region which promotes mitophagy by the formation of an autophagosome. Moreover,
further mitochondrial E3 ubiquitin ligases have been identified to play a role in Parkin-independent
mitophagy are SMAD-specific E3 ubiquitin ligase 1 (Smurf1) and Mul1 [44,45]. Interestingly, Smurf1
relies on its C2 domain for the autophagosome formation instead of the ubiquitin-ligase activity to
interact with SQSMT1/p62, while Mul1 overexpression increases mitochondrial ubiquitination and fission
leading towards mitophagy [46,47].
Evidence suggests that impairments in the PINK1/Parkin pathway play a key role in the
pathogenesis of age-related pulmonary fibrosis [19,48]. A decrease in PINK1, a decrease in autophagy
markers, and an increase in mitochondria mass have been associated with the aging and lungs of IPF
patients. In AECII from IPF lungs, mitochondria have shown dysfunction, evidenced by an enlarged
and dysmorphic structure with severely ruptured cristae [49]. This suggests that accumulation of
dysfunctional mitochondria, in this case, is a consequence of impaired mitophagy, especially in
highly fibrotic areas. Thus, PINK1 is a crucial mitochondrial quality control regulator, not only for
mitophagy but also as a key element in mitochondrial dynamics. PINK1-knockdown increases the
expression of pro-fibrotic peptides, such as TGF-B1 and TGF-B2 in AECII after tunicamycin and
bafilomycin administration [50,51]. In addition, PINK1-deficienct mice exposed to intratracheal
instillation of bleomycin had impaired activity of mitochondrial ETC complex I and IV activity
leading to mitochondrial dysfunction, along with an increased susceptibility to develop lung fibrosis
through upregulation of cytokine TNFα and downregulation of cytokine IL-10 [19,52]. Moreover,
low PINK1 expression correlates with high expression of apoptotic markers, including caspases.
This finding may be attributed to a combination of multiple elements. Evidence shows that
dysmorphic/dysfunctional mitochondria have reduced transmembrane potential, decreased ETC
activity, increased ROS production and increased mitochondrial permeability transition pore, all of
which could lead to activation of pro-fibrotic events in the AECII.
Interestingly, mitophagy homeostasis can be impaired by the upstream effects of increased ER
stress [53,54]. Lung fibrosis has been associated with high ER stress markers. This inappropriate
response to proteostasis alterations leads to the downregulation of PINK1 in AECII through the
expression of ATF3, which acts as a transcriptional repressor of PINK1 [51,55,56]. It has been reported
that patients with IPF have decreased levels of Parkin expression in isolated lung fibroblasts and
myofibroblasts. In addition, Parkin-deficient mice showed an exacerbation of lung fibrosis in the
bleomycin-induced model. Kobayashi et al. reported that impaired mitophagy by Parkin deficiency
induces activation of platelet-derived growth factor receptor (PDGFR)/mammalian target of rapamycin
(mTOR) signaling, prompting differentiation and proliferation of myofibroblast [57]. Furthermore,
Yu et al. linked a potential therapeutic and anti-fibrotic effect of thyroid hormone (TH). In this
study, aerosolized TH resolved fibrosis in two mice models by promoting biogenesis, improving
mitochondrial bioenergetics, and decreasing the apoptosis of AEC in a PPRGC1A or PINK1 dependent
manner. This finding represents a novel approach to reversing fibrotic changes, nonetheless the exact
molecular mechanism is still yet unclear, especially when previous studies have reported reduced
expression of both PINK1 and PPGC1A in IPF lungs [20]. The integrity of the proteins involved in
mitophagy is tightly regulated, for instance, Parkin is regulated by the UPS through its ubiquitin-like
domain that has a high affinity for the subunit Rpn13 of the 26S proteasome. This offers proteasomal
degradation of outer-mitochondrial membranes (OMM) and Parkin degradation once mitophagy has
ended, ensuring proper quality control of this process [58]. In contrast, human IPF lungs have impaired
proteasome activity which leads to the accumulation of misfolded and aggregated proteins in the
ER, suggesting that the decline in mitophagy evidenced in IPF lungs could be associated with high
levels of ER stress and altered activity of the proteasome [59]. Together, these observations highlight
that quality control of this pathway is diminished in lung fibrosis. Mitophagy represents an adaptive
response and a protective role against the development of fibrosis, suggesting manipulation of this
pathway as a potential pharmacological target.
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2.4. Mitochondrial Unfolded Protein Response (UPRmt)
The UPRmt is a stress response pathway that promotes repair and recovery in several conditions,
such as mitochondria DNA defects, ROS detoxification, and perturbations in mitochondrial proteostasis,
protein import machinery or mitochondrial translation. Currently, the molecular mechanism of the
UPRmt has been more broadly described in the model organism Caenorhabditis elegans (C. elegans) than
in mammals. In C. elegans the master regulator of the UPRmt is ATFS-1 [5,60]. However, it is unclear
who the master regulator of the UPRmt is in mammalians. Three possible homologs of ATFS-1 have
been identified; ATF4, ATF5, and CHOP. In C. elegans, under favorable conditions, ATFS-1 is localized
to the mitochondria, where it makes its way to the mitochondrial matrix and is degraded by the
protease, LONP1 [61–63]. However, in the presence of mitochondrial stress, such as unfolded proteins
in the matrix, ATFS-1 will translocate to the nucleus to transcribe UPRmt genes. Unfolded proteins
in the matrix are cleaved by CLPP-1. The cleaved peptides are shuttled out of the mitochondria by
the transporter HAF-1, located in the intermembrane space (IMS). Accumulation of cleaved peptides
prevents mitochondrial transport by inhibiting the action of the translocase of the outer membrane
(TOM) and the translocase of the inner membrane (TIM). As a result, the leucine zipper transcription
factor ATFS-1 is translocated to the nucleus and initiates transcription of genes such as chaperones,
proteases, OXPHOS complexes, and protein import components to promote recovery [64]. In mammals,
it is believed that the UPRmt response is regulated by the actions of three bZIP transcription factors,
CHOP, ATF4 and ATF5. Interestingly, studies have suggested that each of the transcription factors
might play different roles during the response and that activation obeys different stimuli. For instance,
ATF5 is required to increase the expression of mitochondrial chaperones and proteases while ATF4
levels were upregulated in response to mtDNA depletion [65]. At the present time, the regulatory
mechanism of ATF5, CHOP or ATF4 are not completely understood, different from what it is known in
C. elegans with the actions of LONP1 and CLPP-1. In addition, it is not clear how the three transcription
factors coordinate the signaling during the pathway or if activation of each one can occur independently.
Further investigations are needed to understand the different regulatory components of the UPRmt in
order to fully elucidate its role in diseases associated with mitochondrial dysfunction (Figure 3).
The above mentioned is considered the canonical UPRmt pathway, but there are other types of
UPRmt. These other pathways have been described as the UPRmt sirtuin axis, UPRIMS/ERα axis,
and the UPRmt translational axis [66]. While the canonical UPRmt axis aims at restoring proteostasis
through increasing the mitochondria’s ability to fold proteins correctly, the other axis uses other
methods such as stopping translation or removing aberrant proteins. Increased oxidative stress
causes damage to mitochondrial lipids, proteins and mtDNA, resulting in proteotoxic stress in the
mitochondria. A recent study by Papa et al. described the role of the mitochondrial deacetylase
Sirt3 in the UPRmt. Proteotoxic stress activates Sirt3 to coordinate the antioxidant machinery of
the mitochondria by activating the transcription factor FOXOA3 which subsequently increases the
expression of the mitochondria superoxide dismutase MnSOD and catalase. Moreover, SirT3 actions
are required to maintain mitochondrial integrity during proteotoxic stress independently of CHOP
expression [67,68]. Also, inhibition of Sirt3 leads to the downregulation of mitophagy markers
and the activation of apoptotic markers, suggesting a major role in the clearance of damaged or
dysfunctional mitochondria [69]. Furthermore, patients with IPF have increased acetylation of Sirt3
in AEC, leading to decreased activity of this enzyme and increase acetylation of MnSOD and OOG1
in the lung tissue. Jablonski et al. showed that bleomycin exposure to the Sirt3-/- mice augmented
oxidant-induced mtDNA damage, apoptosis, and lung fibrosis while mice overexpressing Sirt3 had
preserved mtDNA and were protected from bleomycin-induced lung fibrosis, highlighting Sirt3 as
key element in maintaining the integrity of the AEC-mtDNA and a potential therapeutic target by
preventing the mtROS injury and apoptosis in IPF [70]. In sum, these findings show the critical role of
Sirt3 as a regulator of mitochondrial network integrity to promote recovery and prevent dysfunction
separately from the actions of the main transcription factors that drive the UPRmt. This pathway,
distinct from the canonical pathway, is referred to as the UPRmt-sirtuin axis.
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Figure 3. Mitochondria unfolded protein response (UPRmt). In both, mammals and C. elegans,
activation of the UPRmt is caused by accumulation of unfolded proteins inside of the mitochondria
matrix. Proteolysis of impaired proteins is carried by the effects of the ClpP protease. In C. elegans,
export of these peptides to the cytosol is accomplished by HAF-1 which activates ATFS-1 (in C. elegans)
or ATF5 (in mammals) to allow nuclear translocation and initiate transcription of this pathway genes.
Physiologically, to prevent unnecessary activation of this signaling, ATFS-1 is imported into the
mitochondria via the mitochondrial-targeting-sequence (MTS), formed by the translocase of the outer
membrane (TOM) and the translocase of the inner membrane (TIM) to allow degradation of ATFS-1
by the protease LON. Furthermore, in C. elegans, translocation to the nucleus of the proteins UBL-5,
LIN-65, MET-1 and MET-2 upon UPRmt activation facilitates the binding of ATFS-1 by chromatin
remodeling. Ultimately, activation of ATFS-1 and ATF5 induces genes to promote OXPHOS recovery,
ROS detoxification, expression of mitochondrial protein import components and upregulation of
chaperones and proteases to re-establish mitochondria proteostasis.
A halt or interference of translation is a hallmark of the UPRmt translational axis, but also of the
integrated stress response (ISR). The ISR is activated under cell stress that is not solely dependent on
the mitochondria. The ISR could be activated as a response to excessive ROS or amino-acid depletion.
Some studies suggest that in order to have UPRmt activation, the ISR must also be activated, however,
the exact mechanism is still unknown. ISR responses are carried by actions of the kinases which
phosphorylate the eukaryotic translation initiation factor 2 subunit 1 (eIF2α). The four kinases known
to phosphorylate eIF2α are GCN2, PERK, HRI, and PKR. Phosphorylation of eIF2α interferes with
the formation of the translation initiation complex. Thus, phosphorylation of eIF2α inhibits protein
translation in the cytoplasm to reduce folding load on mitochondrial chaperones and simultaneously
allowing translation of ISR-specific mRNAs, such as ATF4 [71–74]. While during acute mitochondrial
stress, activation of the ISR enables protein recovery the effects of chronic activation of the ISR-ATF4
pathway are yet to be elucidated. Studies showed that increased expression of ATF4 facilitated the
progression of age-related diseases by modulating the actions of p21 and p27 [65,75]. Hence, suggesting
that mitochondrial dysfunction in aging could lead to chronic activation of the ISR-ATF4 pathway
and overexpression of ATF4 might in fact, be harmful in this setting (Figure 4). Although the exact
mechanism by which mitochondrial dysfunction promotes chronic ISR-ATF4 activation has not yet
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been determined, blockage of this pathway opens a new gate for pharmacological inhibitors to treat
age-related diseases.
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Figure 4. Mitochondria dysfunction and the integrated stress response (ISR). In aging, it is possible that
mitochondrial stress and mitochondria dysfunction caused by mitochondria DNA (mtDNA) damage
activates the integrated stress response (ISR) leading to phosphorylation of the eukaryotic translation
initiation factor 2 subunit 1 (eIF2α) by the kinases GCN2, PERK, HRI and PKR. This causes activation
of the transcription factor 4 (ATF4) to allow protein recovery and promote cellular homeostasis.
Overexpression of ATF4, can modulate the actions of p21, p27, drive the senescence-associated secretory
phenotype (SASP) and stimulate a metabolic reprogramming in the cell that could predispose to
fibrotic disease.
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TGF-B1 and NOX4 in fibroblast of IPF patients, attenuating inflammation and collagen deposition [84,85].
It is well known that PINK1 deficiency in AEC of IPF lungs represents a major factor triggering the
mitochondrial dysfunction seen in these cells. Thus, agents that potentiate the activity of PINK1 can
represent a therapeutic option. The neo-substrate kinetin triphosphate (KTP) showed to increase the
activity of PINK1, Parkin and lower apoptosis markers, establishing this compound as a potential
drug for these patients [86]. Similarly, the induction of the mitochondrial protein SIRT3 represents an
attractive therapeutic option giving its protective effects against injury and fibrosis. A pharmaceutical
compound known as Hexafluoro showed to induce the expression of SIRT3 in mice treated with
bleomycin, lessening the development of lung fibrosis by reducing the expression of collagen 1, a-SMA
and fibronectin through TGF-B1 inhibition [87]. Furthermore, mitochondrial quality control also relies
on the presence of enzyme ubiquitylation to clear damaged mitochondrial proteins. This process is
negatively regulated by de-ubiquitinating enzymes (DUBs) which inhibit mitophagy by removing
the ubiquitin tags added by Parkin. Evidence suggests that the deletion of the de-ubiquitinate USP30,
found in the mitochondrial outer membrane, might represent a novel therapeutic target that could
enhance mitophagy and augment substrate ubiquitination [88,89]. Taken together, pharmacological
modulation of mitochondrial quality control that aims biogenesis, mitophagy and fission/fusion could
lead to the prevention of mitochondrial dysfunction and ultimately, fibrosis. Multiple mechanisms of
actions have been proposed for the different drugs, nonetheless, collective efforts are still required to
fully elucidate the specific molecular mechanism by which many of the suggested compounds exerts
their effect with the goal of providing high-quality therapies that can impact survival in patients with
this condition.
3. Mitochondria in Age-Related Lung Fibrosis
In aging, different models have shown similar decreases in mitochondrial function [90]. Multiple
studies have pointed out that chronic activation of the UPRmt correlates with increased longevity
in C. elegans and mice. However, this activation brings a variety of changes to the mitochondria
network including increased fragmentation, and decreased oxygen consumption and ATP production.
These changes could represent a protective metabolic response to allow mitochondria repair and as
a result prolonged cell survival, or conversely, serve as the initiating factor for the development of
aged-related diseases. Different regulators of the UPRmt have been found to be altered with aging.
For instance, LONP1 expression was reported to be reduced in lung senescence-fibroblast which
lead to the accumulation of oxidized proteins following hydrogen peroxide administration [91–93].
Furthermore, senescence-fibroblasts were shown to have altered mitochondrial mass, suggesting that
perhaps this morphologic change is partially a result of the reduction in the activity of LONP1 with
aging, and could also serve as another explanation for the abnormal morphology observed in the
mitochondria of IPF patients [94,95]. Several reports have demonstrated reduced activity of CLPP-1 in
aged cells. As a result of deficient CLPP-1, cells were shown to have numerous alterations, such as a
higher amount of ROS, decreased ATP production and downregulation of fusion markers, establishing
a link between protease abnormalities, energy metabolism and mitochondrial dynamics [96,97].
In addition, CLPP-1-deficient aged cells were found to have an upregulation of mTORC1 signaling
markers, suggesting that the increased activation of the mTORC1/PGC-1 axis in aged-AECII reported in
our study could be a response to an upstream alteration in the mitochondrial matrix proteases [98,99].
In mammals, efficient regulation of the transcription factors ATF5, ATF4 and CHOP is crucial to
develop proper mitochondria-to-nucleus communication during UPRmt activation, and only a few
studies have described the association of these transcription factors with age-related diseases. Firstly,
ATF5 has been described as an activator of the mTORC pathway resulting in autophagy inhibition
along with inhibition of apoptosis through the expression of BCL-2 anti-apoptotic factor [100,101].
In addition, loss of ATF5 leads to significant apoptosis following thapsigargin (Tg) administration to
induce-ER stress [102]. Altogether, these findings posit ATF5 as a key pro-survival mediator during
proteotoxic damage, a hallmark of age-related diseases. Moreover, multiple aging mice models and
Int. J. Mol. Sci. 2020, 21, 643 11 of 17
AECII from IPF patients have demonstrated increased transcription of ATF4 and CHOP. Studies suggest
that ATF4 induces CHOP, which contributes to the induction of GADD34, the main regulator of a
common adaptive pathway; termed the integrated stress response (ISR), to restore cellular homeostasis
in response to ER stress, depletion of amino-acids and oxidative stress [103–105]. Activation of
this pathway through increased ER stress has been associated with chronic injury and diseases that
ultimately lead to pulmonary fibrosis, such as STFPC-mutations in familial IPF and Hermansky-Pudlak
syndrome, suggesting a link between UPRmt and ER stress as a possible trigger mechanism of the
aberrant fibrotic pattern in lung fibrosis [106,107]. Likewise, the role of CHOP in the development
of lung fibrosis has been described in several reports. In the mouse model of bleomycin-induced
pulmonary fibrosis, CHOP expression was found to be upregulated primarily in AECII of highly fibrotic
areas, while using the same model, CHOP-deficient mice reported a marked reduction of fibrotic areas
and significant lower apoptotic markers [108]. Upregulation of apoptosis-related genes, including
GADD45A and BNIP3L, are modulated by CHOP expression in AEC. Interestingly, activation of
GADD45A is associated with p53 upregulation as a response of DNA damage and apoptosis induction,
increased expression of this protein was found in AEC in IPF [109–112]. Together, these findings
indicate that CHOP plays a key role in the promotion of fibrotic remodeling following chronic injury
and that possibly these effects are triggered by AEC apoptosis, making this transcription factor a target
for future therapeutic prospects.
4. Conclusions
Currently, there are a limited number of marginally effective treatment options for patients with
progressive forms of fibrotic lung disease, emphasizing the need for further mechanistic insight and
translational progress. Evidence that mitochondrial dysfunction initiates fibrotic response is especially
strong in IPF, but the mechanism linking mitochondrial quality control to aberrant repair remains
elusive. Future studies determining how dysregulation of mitochondrial quality control contributes to
the onset or progression of IPF will ultimately be important for advancing understanding of disease
and laying the foundation for new and more effective treatments.
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